CD8A and neoplasm: More importantly, we demonstrated that vaccination with UPs derived from 4T1/EPB cells, but not from 4T1/WT cells, exerted profound anti-tumor effects through augmented cancer-specific CD8+ T cell responses and expanded the diversity of the TCR repertoire.